Pharmaceutical care applied to women with breast cancer in Primary Health Care
DOI:
https://doi.org/10.5902/2236583429900Keywords:
Pharmacotherapeutic follow-up, Clinical Pharmacy, Cancer patientsAbstract
Pharmaceutical care is a pharmacotherapeutic monitoring tool widely used in various health settings. The objective of this research was to perform the pharmacotherapeutic follow-up of female patients belonging to a breast cancer support group - Ellas Group -, linked to the Primary Health Care of a city in the central-western region of the state of Rio Grande do Sul. followup methodology was performed according to the Dáder Method. Eighteen non-pharmacological interventions were performed for the study patients, after being submitted there are an average of three pharmaceutical consultations with each patient. The mean age of the study participants was 54.1 years (SD = 8.2). The mean age of menopause was 44.4 years (SD = 8.2) and the age of menarche was 13.2 years (SD = 2.0). Three drug-related problems and nine negative drug outcomes were identified. In agreement with the proposed objective, it was verified how important it is to institute in the pharmaceutical practice the tools of care and pharmacotherapeutic monitoring in different clinical scenarios.Downloads
References
Instituto Nacional do Câncer José Alencar Gomes da Silva (INCA). ABC do câncer: abordagens básicas para o controle do câncer. 2a ed. Rio de Janeiro/RJ: INCA; 2011.
Smeltzer SC, Bare GB, Brunner & Suddarth. Tratado de Enfermagem Médico- Cirúrgica. 10a ed. Rio de Janeiro: Guanabara Koogan; 2005.
Weidle P, Bradley L, Gallina J, Mullins CD, Thorn D, Siegel LP. Pharmaceutical care intervention documentation program and related cost savings at a university hospital. Lippincott’s Hospital Pharmacy. 1999; 34(1): 43-52.
Narhi U, Airaksinen M, Tansknanen P, Erlund H. Terapeutic outcomes monitoring by community pharmacists for improving clinical outcomes in asthma. J. Clin. Pharm. Ther. 2000; 25(3):177-83.
Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Rundberger E. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven Europcan countries. Drug Aging. 2001; 18(1):63-77.
Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica Insumos Estratégicos. Serviços farmacêuticos na atenção básica à saúde. Brasília: Ministério da Saúde, 2014.
Hernández DS, Castro MMS, Dáder MJF. Método Dáder: manual de seguimento farmacoterapêutico. 3a ed. Grupo de Investigación en Atención Farmacéutica (CTS-131). Granada (Espanha): Universidad de Granada; 2014.
Conselho Nacional de Saúde (Brasil). Resolução nº. 466, de 12 de dezembro de 2012. Brasília; 2012.
Fernandes FS. Testes de Ajuste a Distribuições Estatísticas e Métodos para Estimação dos Parâmetros em Análises de Fiabilidade [dissertação]. Lisboa (Portugal): Instituto Superior de Engenharia de Lisboa; 2013.
Mota DM, Silva MGC, Sudo EC, Ortún V. Uso racional de medicamentos: uma abordagem econômica para tomada de decisões. Ciênc. saúde coletiva [Internet]. 2008 Apr [cited 2018 Mar 22]; 13(Suppl): 589-601.
Santos HJ, Iglésias-Ferreira P, Ribeiro PL, Nunes-da-Cunha I. Introdução ao seguimento farmacoterapêutico. Lisboa (Portugal): Universidade Lusófona; 2007.
Smith RA, D’Orsi CJ. Screening for breast cancer. In: Harris Jr., Lipmann ME, Morrow M, Osborne CK, editors. Diseases of the breast. Philadelphia: Lippincott; 2005. p.103-30.
Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer. 1986; 57: 2217-21. Errata em: Cancer, 1986; 58(4):996.
Santi M, Capocaccia R, Verdecchia A, Esteve J, Gatta G, Micheli A. Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. Int J Cancer. 1998; 77:679-83.
Abreu E, Koifman J. Fatores prognósticos no câncer de mama feminino. Rev. Brasileira de Cancerologia. 2002;
(48):113-31.
Borges TT, Rombaldi AJ, Knuth AG, Hallal PC. Conhecimento sobre fatores de risco para doenças crônicas:
estudo de base populacional. Cad. Saúde Púb. 2009; 25(7):1511-1520.
Vogel VG. Breast cancer prevention: a review of current evidence. J. Clinic. Oncol. 2000; 50(3):156-70.
Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE. A prospective study of endogenous estrogens and breast cancer in post menopausal women. J Natl Cancer Inst. 1995; 87(3):190.
Moerkens M, Zhang Y, Wester L, Van de Water B, Meerman JH. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014; 1(14):283.
Zapaterini JR. Avaliação histopatológica e molecular da imunoterapia com p-mapa associada ao tamoxifeno na progressão do câncer de mama induzido quimicamente em ratas Sprague-Dawley [dissertação]. São Paulo: Universidade Estadual Paulista “Júlio de Mesquita Filho” Câmpus de Botucatu; 2017.
Silva LC. Câncer de mama e sofrimento psicológico: aspectos relacionados ao feminino. Psico. Est. 2008; 13(2): 231-237
Cantinelli FS et al. A oncopsiquiatria no câncer de mama – considerações a respeito de questões do feminino. Rev. de Psiquiatria Clínica. 2006; 3(33):124-133.
Henson DE, Ries L, Freedman MA, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22.616 cases of breast cancer. Cancer; 1991. 68:2142-2149.
Simons S, Ringsdorf S, Braun M. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Supportive Care in Cancer; 2011. 7(20):1009-1018.
